Shining light on nuclear-targeted therapy using gold nanostar constructs.

作者: Duncan Hieu M Dam , Kayla SB Culver , Patrick N Sisco , Teri W Odom

DOI: 10.4155/TDE.12.107

关键词:

摘要: Nuclear-targeted therapy has received increasing attention as a potential strategy to improve the therapeutic efficacy of treating cancer. The main challenges include targeting, drug-delivery efficiency and release anticancer agents cancer cell nucleus. Nanoparticles nanocarriers have started address some these issues. However, lack understanding in how nanoconstructs interact with nucleus precluded detailed studies. In this article, we highlight nanoconstruct composed gold (Au) nanostars loaded nucleolin-specific aptamers. This induced major changes nuclear phenotype through envelope (NE) invaginations. Femtosecond, light-triggered aptamers from surface Au further increased number NE deformations. Cancer cells more folding showed apoptosis well decreased viability. author’s article revealed that correlation between drug-induced phenotypes can provide new insight into nuclear-targeted therapy.

参考文章(32)
R. K. Stuart, K. Stockerl-Goldstein, M. Cooper, M. Devetten, R. Herzig, B. Medeiros, G. Schiller, A. Wei, G. Acton, D. Rizzieri, Randomized phase II trial of the nucleolin targeting aptamer AS1411 combined with high-dose cytarabine in relapsed/refractory acute myeloid leukemia (AML) Journal of Clinical Oncology. ,vol. 27, pp. 7019- 7019 ,(2009) , 10.1200/JCO.2009.27.15_SUPPL.7019
P McLaughlin, A J Grillo-López, B K Link, R Levy, M S Czuczman, M E Williams, M R Heyman, I Bence-Bruckler, C A White, F Cabanillas, V Jain, A D Ho, J Lister, K Wey, D Shen, B K Dallaire, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology. ,vol. 16, pp. 2825- 2833 ,(1998) , 10.1200/JCO.1998.16.8.2825
Joan Albanell, Larry Norton, Jose Baselga, Young Mee Kim, John Mendelsohn, Recombinant Humanized anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin Against HER2/neu Overexpressing Human Breast Cancer Xenografts Cancer Research. ,vol. 58, pp. 2825- 2831 ,(1998)
Guido Kroemer, Lorenzo Galluzzi, Catherine Brenner, Mitochondrial Membrane Permeabilization in Cell Death Physiological Reviews. ,vol. 87, pp. 99- 163 ,(2007) , 10.1152/PHYSREV.00013.2006
Jesus M. de la Fuente, Catherine C. Berry, Tat peptide as an efficient molecule to translocate gold nanoparticles into the cell nucleus. Bioconjugate Chemistry. ,vol. 16, pp. 1176- 1180 ,(2005) , 10.1021/BC050033+
Sridharan Soundararajan, Li Wang, Vijayalakshmi Sridharan, Weiwei Chen, Nigel Courtenay-Luck, David Jones, Eleanor K. Spicer, Daniel J. Fernandes, Plasma Membrane Nucleolin Is a Receptor for the Anticancer Aptamer AS1411 in MV4-11 Leukemia Cells Molecular Pharmacology. ,vol. 76, pp. 984- 991 ,(2009) , 10.1124/MOL.109.055947
Nathalie Symens, Rudolf Walczak, Joseph Demeester, Iain Mattaj, Stefaan C. De Smedt, Katrien Remaut, Nuclear inclusion of nontargeted and chromatin-targeted polystyrene beads and plasmid DNA containing nanoparticles. Molecular Pharmaceutics. ,vol. 8, pp. 1757- 1766 ,(2011) , 10.1021/MP200120V
R S Faustino, T J Nelson, A Terzic, C Perez-Terzic, Nuclear Transport: Target for Therapy Clinical Pharmacology & Therapeutics. ,vol. 81, pp. 880- 886 ,(2007) , 10.1038/SJ.CLPT.6100141
Limin Pan, Qianjun He, Jianan Liu, Yu Chen, Ming Ma, Linlin Zhang, Jianlin Shi, Nuclear-targeted drug delivery of TAT peptide-conjugated monodisperse mesoporous silica nanoparticles. Journal of the American Chemical Society. ,vol. 134, pp. 5722- 5725 ,(2012) , 10.1021/JA211035W
Gary K. Schwartz, Manish A. Shah, Targeting the Cell Cycle: A New Approach to Cancer Therapy Journal of Clinical Oncology. ,vol. 23, pp. 9408- 9421 ,(2005) , 10.1200/JCO.2005.01.5594